Lupin appoints Spiro Gavaris as President of US Generics Business

9 Dec 2022 , 09:16 AM

Global pharma major Lupin Limited has announced the appointment of Spiro Gavaris as President U.S. Generics business. As part of Lupin’s senior leadership team, Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business.

Spiro joins Lupin with significant experience in the branded, generic and biotech industries. He most recently served as President of Specialty Generics business at Mallinckrodt Pharmaceuticals and the President of US Injectables at Hikma.

Commenting on the appointment, Vinita Gupta, CEO, Lupin said, “Spiro brings strong pharma and biotech experience and has an established track record of success in building generics business across platforms, and in particular on the injectables front.

We are delighted to welcome him to our leadership team.”

On Friday early morning trade, Lupin Ltd is currently trading at Rs757.40 per share up by Rs2.85 or 0.38% from its previous closing of Rs754.55 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]